Sanofi-Aventis U.S. LLC
Sanofi-Aventis U.S. LLC, a prominent subsidiary of the global healthcare leader Sanofi, is headquartered in the United States, with significant operations across North America. Founded in 2004, the company has established itself within the pharmaceutical industry, focusing on innovative solutions in areas such as diabetes, cardiovascular health, and rare diseases.
Sanofi-Aventis is renowned for its diverse portfolio of core products, including insulin therapies and vaccines, which are distinguished by their commitment to patient-centric care and advanced research. The company has achieved notable milestones, including advancements in biologics and a strong market position as a trusted provider of essential medications. With a dedication to improving health outcomes, Sanofi-Aventis continues to play a vital role in the evolving landscape of global healthcare.
+62 vs industry average
Sanofi-Aventis U.S. LLC’s score of 100 is higher than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Sanofi-Aventis U.S. LLC?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing has below-average carbon intensity
Industry performance
The Pharmaceutical Preparation Manufacturing industry has reduced its overall emissions by 19% since 0
Reported emissions
No reported emissions data is available for Sanofi-Aventis U.S. LLC yet.
Sanofi-Aventis U.S. LLC's reported carbon emissions
Sanofi-Aventis U.S. LLC, headquartered in the US, currently does not have specific carbon emissions data available for the most recent year, as indicated by the absence of emissions figures. The company is a current subsidiary of Sanofi, which cascades its climate commitments and emissions data from the parent organisation.
Sanofi has set various climate initiatives, including targets under the Science Based Targets initiative (SBTi), and participates in the Carbon Disclosure Project (CDP) and RE100, which focuses on renewable energy commitments. However, specific reduction targets or achievements for Sanofi-Aventis U.S. LLC are not detailed in the available information.
As a part of the broader Sanofi corporate family, the climate commitments and performance metrics are inherited from the parent company, Sanofi. This relationship underscores the importance of collective action within the pharmaceutical industry to address climate change and reduce carbon footprints.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Sanofi-Aventis U.S. LLC’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Sanofi-Aventis U.S. LLC yet.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Climate initiatives

Science Based Targets Initiative
Inherited from Sanofi
Carbon Disclosure Project
Inherited from SanofiThe Climate Pledge
UN Global Compact Climate Champions initiative
Inherited from SanofiRE 100
Inherited from SanofiClimate Action 100
Emissions comparison with industry peers
View similar organisationsUsage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project